LATEST ALERTS
The FDA recently rejected applications from both Charlotte’s Web and Irwin Naturals to use a hemp extract as a dietary supplement
There remains no certainty over the future regulation of ingestible CBD products in many jurisdictions
The US Postal Service (USPS) is still shipping CBD vape products for now – but the latest version of the Prevent All Cigarette Trafficking (PACT) Act leaves a lot of uncertainty over the exact legal position
A CBD company’s punishment by the US Federal Trade Commission (FTC) for making false or misleading health claims has been confirmed
Licensing issues look set to become the next big US lobbying battleground for cannabis as money moves on from the traditional legalisation-versus-prohibition field
Lina Khan’s appointment to chair the US Federal Trade Commission (FTC) – confirmed last month – was a bit of a surprise
As CBD grows in popularity, its regulatory status remains poorly defined. In this report CBD-Intel reviews the regulatory framework of dietary supplements and where CBD fits, or would fit, within that framework
Delta-8 THC has emerged as the hottest new cannabinoid in the US market. This report examines federal law on delta-8, notes trends that are happening at state level, and discusses what the future may hold
A CBD company has been fined more than $30,000 by the US Federal Trade Commission (FTC) in the first such punishment since a crackdown on false or misleading health claims was announced in December
Significant cannabis reform is inevitably coming to congress, no matter whether the Biden administration considers it a priority, and giants in experienced lobbying industries are preparing their agents
A new deputy commissioner at the US Food and Drug Administration (FDA) will likely be the single person with the most influence on the path to market for CBD in the US
Access to banking services has been a problem for the legal cannabis sector in the US from the beginning – and the experience of one cooperative in Michigan shows that the relationship can be problematic for financial institutions too
The US Customs and Border Protection (CBP) agency is wrongly seizing legal hemp and hemp-related shipments – such as farm equipment that it claims constitutes drug paraphernalia – according to two recently-filed lawsuits
CBD companies see more synergies than threats from the provision of legal cannabis products in states such as Colorado, which has one of the oldest recreational cannabis markets in the US
The US Food and Drug Administration (FDA) has assessed a combined health claim for the first time and denounced the practice of promoting CBD on a product making qualified health claims based on other ingredients
The US Food and Drug Administration (FDA) has told two CBD companies they fell short of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and ordered them to undertake proper testing
CBD-Intel podcasts editor Jon Bruford is joined by the founder and principal of Kight Law Office, Rod Kight, a specialist in cannabis business law in the US
The heir to the Wrigley’s chewing gum fortune, Beau Wrigley, has entered into a deal he claims will accelerate the growth of his multi-state cannabis company, Parallel, and change the landscape of the US cannabis market
Marlboro cigarette manufacturer Altria has stated its support for the federal legalisation of cannabis – with a view to Cronos, the Canadian cannabis company in which it has a major stake, thriving in a legal US market
A US association of cannabis regulators has written to Congress urging the modernisation of cannabis policy at federal level
The US Federal Trade Commission (FTC) could take a more discerning approach to enforcement against CBD companies under the new administration in Washington
The Democratic Party, which now controls Congress and the presidency, has signalled for some time that cannabis reform is one of its top priorities, and the US public supports that reform in unprecedented numbers
US president Joe Biden’s appointees to a number of influential positions in the new administration give reason for optimism within the hemp and cannabis sector
The US Small Business Administration (SBA) has highlighted its role in securing changes to the Department of Agriculture (USDA)’s final rule for hemp production
CBD-Intel presents some predictions of what regulatory moves could take place around cannabis, hemp and CBD in the US in 2021
President elect Joe Biden still looks to be somewhat reluctant to too closely embrace cannabis reform as an issue. But effective control of the senate through victories by Raphael Warnock and Jon Ossoff in special run-off elections in the state of Georgia give Democrats 48 seats with two independents that generally vote democratic (and would certainly do so on most » Continue Reading.
Reform of cannabis laws at federal level in the US looks to be a step closer following the likely victory of the Democratic party in run-off elections for both Senate seats in the state of Georgia
For many 2020 will always carry an asterisk. The CBD industry was – overall – more fortunate than many other sectors
Multiple jurisdictions are planning significant legislation on both CBD and hemp-related matters, but it seems regulation in 2021 could be defined as much by what doesn’t happen as by the progress made
The US Food and Drug Administration (FDA) is still working on a plan to standardise a baseline level of regulation for CBD in dietary supplements, food and drinks – but many in the industry and at state level are weary of waiting
Claims that CBD could help shrink tumours were among those censured by the US Food and Drug Administration (FDA) in its latest round of warning letters to the industry
The first ever fines – ranging up to $85,000 – have been issued to CBD companies by the US Federal Trade Commission (FTC) for deceptive marketing practices
Another company has been warned by the US Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) to stop claiming CBD can cure or mitigate the symptoms of COVID-19
With Joe Biden poised to become the 46th US president, lobbyists in Washington are scrambling to position themselves to influence cannabis policy
Expect US Food and Drug Administration (FDA) regulations on CBD by the second half of 2021, according to leading brand Charlotte’s Web
The US Food and Drug Administration (FDA) may be open to allowing CBD as an ingredient in dietary supplements as well as in food and drink products. However, the regulatory pathway is not clear
Investing activity in the cannabis space is on the rise, as investors take advantage of lower prices and companies seek opportunities to merge – bolstered by anticipated changes at US federal level
Well reported studies of labelling issues give unfair bad press to CBD – but it is an issue the industry urgently needs to address, according to speakers at the Food and Drug Law Institute’s annual conference
It remains unclear when, or whether, US FDA guidance on CBD enforcement policy will be published, according to speakers at the recent Food and Drug Law Institute annual conference
The National Advertising Division (NAD) of the US Better Business Bureau has referred advertising claims made by a CBD company to the Federal Trade Commission (FTC)
With US elections on 3rd November fast approaching, lobbyists for CBD, cannabis and hemp are eager to get their message across to candidates on both sides of the political divide
The apparently unrelated fields of red yeast rice and stem cell research could provide clues as to how the US Food and Drug Administration (FDA) might deal with market regulation of CBD
Should CBD or cannabis companies invest in the US or Canada? There are pros and cons to each, and the same answer may not apply to everyone – or remain the same forever
The US Congress has extended by 11 months the deadline for states to get into compliance with the 2018 Farm Bill
The US House of Representatives is expected to hold a historic vote this month on a comprehensive cannabis reform bill that supporters embrace for not only decriminalising marijuana but correcting injustices
More than a dozen CBD businesses have given their backing to an investigation of the impact of CBD on liver toxicity levels in order to provide regulatory authorities in the US with reliable new data
First it’s important to note that the DEA proposals are only in a draft form and are open to comment until 20th October. They have already received a large number of comments, the majority of which appear to be criticising aspects of the proposed regulatory regime that have raised hackles among the industry.
The pharmaceutical side of the cannabinoid industry continues to grow, with several major announcements expanding treatments and blurring boundaries
Proposed regulations from the US Drug Enforcement Administration (DEA) have riled the hemp and CBD sectors, with opinions divided on what the rule would mean if enacted in its current form
Charlotte’s Web has been denied a US trademark on appeal – a ruling that has serious implications for any company in the CBD sector selling food, drink or dietary supplement products in the US
Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.
"*" indicates required fields
Get 7 days of access to industry updates through our news analysis and regulatory alerts
"*" indicates required fields
Notifications
